Safety of immune checkpoint inhibitors in patients with cancer and pre-existing autoimmune disease.

ABSTRACT:

Background

Patients with pre-existing autoimmune disease (AD) have been largely excluded from clinical trials of immune checkpoint inhibitors (ICI), so data on safety of ICIs among patients with pre-existing AD are relatively limited. There is a need for deeper understanding of the type and management of complications from ICI in patients with pre-existing AD. We sought to investigate the safety of ICIs in patients with pre-existing ADs as well as factors associated with AD flare.

Methods

Consecutive patients with pre-existing AD who received monotherapy as well as combination of ICI therapies at our institution from September 2015 through September 1^st, 2018 were identified. Clinical information was abstracted via manual chart review. Clinical factors associated

SUBMITTER: Alexander S 

PROVIDER: S-EPMC8267316 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature